Xellia is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases.
Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to Research and Development sites in Norway and Croatia, Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers.
The Global Finance Center has been established in Budapest in 2015 and supports Denmark, Norway, Croatia, Hungary and soon the US operations.